Market LIVE
Published markets; coverage varies by country
Product profile · United States

ZEPBOUND KWIKPEN

 ·  Patent Litigation & Settlement History ↓

IngredientTIRZEPATIDE
Application typeNDA
Application217806
Product022
Dosage formSOLUTION
RouteSUBCUTANEOUS
Strength40MG/2.4ML (16.7MG/ML)
Approval date2026-01-20
Marketing statusPrescription
Status event—
ApplicantELI LILLY AND CO
Product source

Current GenericRadar decision

Year2036
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeTRUE_DS_PATENT
Anchor date2036-05-13
Patent anchor2036-05-13
Exclusivity anchor2027-05-13
Protection date—
First Final ANDA—
Status event—

QUALIFYING_ANCHOR_WITH_LATER_RIGHTS; Full-scope patent/exclusivity review completed.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
94747802036-05-13DS/DP ————
———
123433822039-07-22U U-4409———
———
123433822039-07-22U U-4228———
———
123433822039-07-22U U-4227———
———
123433822039-07-22U U-4410———
———
124537582039-07-22U U-4308———
———
124537582039-07-22U U-4309———
———
124537582039-07-22U U-4311———
———
124537582039-07-22U U-4310———
———
126167402039-07-22U U-4499———
———
126167402039-07-22U U-4497———
———
126167402039-07-22U U-4498———
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE—2027-05-13————Source
M-82—2027-10-18————Source
I-958—2027-12-20————Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (1)
TypeDateRoleBasisSource
FULL_YEAR_RECHECK—ANCHOR_AND_TAILExact products013-024: US9474780 anchor2036-05-13. US12343382,12453758,12616740 U tails2039-07-22 retained. Weight-management claims not automatically treated as covering all OSA use. Separate approvals2026-01-07/2026-01-20 preserved.Source
Decision history
CurrentYearStatusReviewAnchorJudged
Y2036DEEP_REVIEWFINAL2036-05-132026-10-17 23:57:57
N2036DEEP_REVIEWFINAL2036-05-132026-10-14 08:07:38
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.